Search Result

Results for "

acute pulmonary diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Akt (3) Apoptosis (3) Autophagy (3) c-Fms (1) Carnitine Palmitoyltransferase (CPT) (2) CCR (2) COX (1) Elastase (1) Formyl Peptide Receptor (FPR) (2) IKK (1) Insecticide (2) Interleukin Related (3) Itk (1) Keap1-Nrf2 (4) MMP (2) NF-κB (5) NOD-like Receptor (NLR) (1) p38 MAPK (1) PAI-1 (1) Phosphatase (1) Phosphodiesterase (PDE) (2) PI3K (2) RANKL/RANK (1) Reactive Oxygen Species (ROS) (3) Reference Standards (4) Ser/Thr Protease (1) STAT (1) TGF-β Receptor (1) Thrombin (1) Thymidylate Synthase (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Endocrinology (1) Infection (2) Inflammation/Immunology (18) Metabolic Disease (2) Neurological Disease (2)

By Targets:

Adrenergic Receptor (1)

Akt (3)

Apoptosis (3)

Autophagy (3)

c-Fms (1)

Carnitine Palmitoyltransferase (CPT) (2)

CCR (2)

COX (1)

Elastase (1)

Formyl Peptide Receptor (FPR) (2)

IKK (1)

Insecticide (2)

Interleukin Related (3)

Itk (1)

Keap1-Nrf2 (4)

MMP (2)

NF-κB (5)

NOD-like Receptor (NLR) (1)

p38 MAPK (1)

PAI-1 (1)

Phosphatase (1)

Phosphodiesterase (PDE) (2)

PI3K (2)

RANKL/RANK (1)

Reactive Oxygen Species (ROS) (3)

Reference Standards (4)

Ser/Thr Protease (1)

STAT (1)

TGF-β Receptor (1)

Thrombin (1)

Thymidylate Synthase (2)

By Research Areas:

Cancer (6)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (18)

Metabolic Disease (2)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150298

Soquelitinib 3 Publications Verification CPI-818	Itk	Inflammation/Immunology Cancer
Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 ⁺ cells that possess enhanced T effector function .

HY-101283

HCH6-1 5 Publications Verification	Formyl Peptide Receptor (FPR)	Inflammation/Immunology
HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .

HY-N2593

Isorhapontigenin 4 Publications Verification	Carnitine Palmitoyltransferase (CPT) Reactive Oxygen Species (ROS) Autophagy Apoptosis NF-κB PI3K Akt MMP Keap1-Nrf2	Metabolic Disease Inflammation/Immunology Cancer
Isorhapontigenin is an orally active dietary polyphenol. Isorhapontigenin acts as a potent antioxidant that reduces the production of reactive oxygen species (ROS). Isorhapontigenin promotes the binding of JUN to the AP-1 site on the SESN2 promoter, induces SESN2 transcription, triggers MAPK8-dependent JUN activation, and upregulates the expression of PPAR-α, PGC-1α and CPT-1A to facilitate fatty acid oxidation. Isorhapontigenin induces autophagy, apoptosis and preadipocyte differentiation; it inhibits tumor growth, cell invasion, NF-κB transcriptional activity, the PI3K/Akt signaling pathway, STAT1 phosphorylation and MMP-2 expression. Isorhapontigenin alleviates oxidative stress, inflammatory cytokine release and triglyceride accumulation; it increases intracellular ATP levels and promotes Nrf2 nuclear translocation. Isorhapontigenin improves insulin sensitivity in adipose tissue and glucose tolerance, and reduces postprandial blood glucose, insulin and free fatty acid levels. Isorhapontigenin is applicable to research on bladder cancer, liver injury, chronic obstructive pulmonary disease, acute lung injury and type 2 diabetes .

HY-103363

SB-328437 3 Publications Verification	CCR Thymidylate Synthase	Inflammation/Immunology Cancer
SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC₅₀ of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .

HY-P990094

Trabikibart CSL311	c-Fms	Inflammation/Immunology
Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps .

HY-123936

SR12343	NF-κB IKK COX Interleukin Related	Neurological Disease Inflammation/Immunology
SR12343 is a IKK/NF-κB inhibitor and a mimetic of the NF-κB essential modulator (NEMO)-binding domain (NBD). SR12343 inhibits TNF-α- and LPS-induced NF-κB activation by blocking the interaction between IKKβ and NEMO. SR12343 suppresses LPS-induced acute pulmonary inflammation in mice. SR12343 extends the healthspan of naturally aged and accelerated aging mice. SR12343 can be used for research on inflammatory and degenerative diseases .

HY-118177

Neutrophil elastase inhibitor 1	Elastase Thrombin Ser/Thr Protease	Inflammation/Immunology
Neutrophil elastase inhibitor 1 is a competitive, pseudo-reversible inhibitor of human neutrophil elastase (HNE) with an IC₅₀ of 7 nM. Neutrophil elastase inhibitor 1 also exhibits inhibitory activity against thrombin, chymotrypsin and urokinase, with IC₅₀ values of 1.9 μM, 66 nM and 6.6 μM, respectively. Neutrophil elastase inhibitor 1 can be used in research related to acute respiratory distress syndrome, chronic obstructive pulmonary disease and other conditions .

HY-N1956

Rubiadin-1-methyl ether 1 Publications Verification	NF-κB RANKL/RANK Autophagy TGF-β Receptor	Metabolic Disease Inflammation/Immunology
Rubiadin-1-methyl ether is an orally potent NF-κB p65 inhibitor and autophagy inhibitor. Rubiadin-1-methyl ether inhibits RANKL-induced phosphorylation and nuclear translocation of p65, suppresses BECN1 transcription, blocks LC3 conversion and autophagosome formation, thereby reducing the levels of BECN1 mRNA and Beclin1 protein. Rubiadin-1-methyl ether inhibits osteoclastogenesis, cell proliferation, macrophage M2 polarization and the TGF-β1 signaling pathway, and effectively alleviates pulmonary inflammation. Rubiadin-1-methyl ether is widely used in research on osteoporosis, pulmonary fibrosis, idiopathic pulmonary fibrosis, acute lung injury and other related diseases .

HY-P10868

Pegtarazimod RLS-0071	Reactive Oxygen Species (ROS)	Infection Inflammation/Immunology
Pegtarazimod (RLS-0071) is a dual-target anti-inflammatory peptide that exerts its effects by simultaneously regulating the complement system and neutrophil-associated inflammatory pathways. Pegtarazimod reduces ROS production both in vitro and in vivo, and decreases the level of neutrophil elastase, a marker of neutrophil extracellular traps (NETs), in vivo, thereby alleviating inflammatory responses. Pegtarazimod significantly improves the survival rate of mice in multiple in vivo models of acute graft-versus-host disease (aGVHD). Pegtarazimod inhibits the activation of the C1 complex, reduces the herpes zoster-like spread of herpes simplex virus type 1 skin infection, and improves the survival rate of infected mice . Pegtarazimod can be used in research related to acute graft-versus-host disease, acute pulmonary diseases, and skin herpes simplex virus type 1 infection .

HY-145390A

(R,R)-Nrf2 activator-1	Keap1-Nrf2	Inflammation/Immunology
(R,R)-Nrf2 activator-1 is the enantiomer of Nrf2 activator-1. Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis .

HY-W075176

Transfluthrin	Insecticide	Infection
Transfluthrin is an insecticide with extremely low acute toxicity to vertebrates. Transfluthrin acts as a mosquito repellent, exerts mosquito control effects via electric heating fumigators, and is widely used in studies related to malaria, bancroftian filariasis and mosquito-borne infectious diseases. Transfluthrin may also induce adverse reactions such as pulmonary sensory irritation, sensitization, genotoxicity and respiratory depression, and can increase the concentrations and activities of CYP2E1 and CYP3A2 in rat brains. Transfluthrin can be removed from wastewater through biodegradation and activated sludge adsorption, and can be degraded by microorganisms such as Azovibrio and Tauera .

HY-145390

Nrf2 activator-1	Keap1-Nrf2	Inflammation/Immunology
Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the research of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis (extracted from patent WO2018109647A1) .

HY-110169

(E/Z)-3PO	Phosphatase	Cardiovascular Disease Cancer
(E/Z)-3PO is a potent PFKFB3 inhibitor. (E/Z)-3PO can inhibit the glycolysis process, reduce the extracellular acidification rate, and inhibit the capillary tube formation, migration of endothelial cells, and the formation of aortic sprouts, thereby suppressing angiogenesis. (E/Z)-3PO is promising for research of diseases such as cancer, acute lung injury, pulmonary fibrosis, and atherosclerosis .

HY-W075176R

Transfluthrin (Standard)	Insecticide Reference Standards	Others
Transfluthrin (Standard) is the analytical standard of Transfluthrin (HY-W075176). This product is intended for research and analytical applications. Transfluthrin is an insecticide with extremely low acute toxicity to vertebrates. Transfluthrin acts as a mosquito repellent, exerts mosquito control effects via electric heating fumigators, and is widely used in studies related to malaria, bancroftian filariasis and mosquito-borne infectious diseases. Transfluthrin may also induce adverse reactions such as pulmonary sensory irritation, sensitization, genotoxicity and respiratory depression, and can increase the concentrations and activities of CYP2E1 and CYP3A2 in rat brains. Transfluthrin can be removed from wastewater through biodegradation and activated sludge adsorption, and can be degraded by microorganisms such as Azovibrio and Tauera .

HY-167891

GPD-1116	Phosphodiesterase (PDE) Apoptosis	Inflammation/Immunology
GPD-1116 is an orally active Phosphodiesterase (PDE) 4 and PDE1 inhibitor. GPD-1116 can reduce smoke-induced apoptosis of lung cells. GPD-1116 is effective in several disease models in animals, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma and pulmonary hypertension .

HY-172135

PDE4-IN-26	p38 MAPK Phosphodiesterase (PDE)	Inflammation/Immunology
PDE4-IN-26 (Compound A5) is an orally active and highly selective PDE4 inhibitor. PDE4-IN-26 has anti-inflammatory activity and can inhibit the phosphorylation of p38 MAPK. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 can improve pulmonary inflammation, injury and fibrosis, promote sputum secretion and relieve cough in mice. PDE4-IN-26 can be used for the research of lung injury-related diseases .

HY-P10854

TAT-N15	NF-κB Interleukin Related STAT Akt	Neurological Disease Inflammation/Immunology
TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke .

HY-14915

Bedoradrine	Adrenergic Receptor	Endocrinology
Bedoradrine is a highly selective β2-adrenergic agonist with activity in suppressing asthma and chronic obstructive pulmonary disease (COPD). Bedoradrine is administered by intravenous infusion and is specifically indicated for the suppression of acute asthma attacks. Bedoradrine has shown good safety and preliminary efficacy in clinical trials, especially in patients with stable moderate to severe asthma. The results of Bedoradrine studies have shown that it can provide clinical benefits without increasing clinical risks, especially for patients who are unable to use inhalation or nebulization suppression .

HY-N2593R

Isorhapontigenin (Standard)	Reference Standards Carnitine Palmitoyltransferase (CPT) Reactive Oxygen Species (ROS) Autophagy Apoptosis NF-κB PI3K Akt MMP Keap1-Nrf2	Inflammation/Immunology Cancer
Isorhapontigenin (Standard) is the analytical standard of Isorhapontigenin (HY-N2593). This product is intended for research and analytical applications. Isorhapontigenin is an orally active dietary polyphenol. Isorhapontigenin acts as a potent antioxidant that reduces the production of reactive oxygen species (ROS). Isorhapontigenin promotes the binding of JUN to the AP-1 site on the SESN2 promoter, induces SESN2 transcription, triggers MAPK8-dependent JUN activation, and upregulates the expression of PPAR-α, PGC-1α and CPT-1A to facilitate fatty acid oxidation. Isorhapontigenin induces autophagy, apoptosis and preadipocyte differentiation; it inhibits tumor growth, cell invasion, NF-κB transcriptional activity, the PI3K/Akt signaling pathway, STAT1 phosphorylation and MMP-2 expression. Isorhapontigenin alleviates oxidative stress, inflammatory cytokine release and triglyceride accumulation; it increases intracellular ATP levels and promotes Nrf2 nuclear translocation. Isorhapontigenin improves insulin sensitivity in adipose tissue and glucose tolerance, and reduces postprandial blood glucose, insulin and free fatty acid levels. Isorhapontigenin is applicable to research on bladder cancer, liver injury, chronic obstructive pulmonary disease, acute lung injury and type 2 diabetes.

HY-183337

ZM734	NOD-like Receptor (NLR) Interleukin Related	Inflammation/Immunology
ZM734 is an orally active and selective NLRP3 inflammasome inhibitor. ZM734 inhibits the secretion of IL-1β. ZM734 alleviates pulmonary inflammation in a mouse model of acute lung injury. ZM734 can be used for the research of inflammatory diseases such as acute lung injury .

HY-113769

WB 3559 A	PAI-1	Cardiovascular Disease
WB 3559 A is a fibrinolytic plasminogen activator. WB 3559 A accelerates the conversion of plasminogen to plasmin and directly degrades fibrin in thrombi. WB 3559 A is promising for research of acute thrombotic diseases (e.g., myocardial infarction, pulmonary embolism) .

HY-101283R

HCH6-1 (Standard)	Formyl Peptide Receptor (FPR) Reference Standards	Inflammation/Immunology
HCH6-1 (Standard) is the analytical standard of HCH6-1 (HY-101283). This product is intended for research and analytical applications. HCH6-1 is a potent and competitive dipeptide antagonist of Formyl peptide receptor 1 (FPR1). HCH6-1 inhibits chemotaxis, superoxide anion generation, and elastase release in human neutrophils specifically activated by fMLF (an FPR1 agonist). HCH6-1 has protective effects against acute lung injury (ALI) in vivo and can be used for the research of FPR1-involved inflammatory lung diseases .

HY-103363R

SB-328437 (Standard)	Reference Standards CCR Thymidylate Synthase	Inflammation/Immunology Cancer
SB-328437 (Standard) is the analytical standard of SB-328437 (HY-103363). This product is intended for research and analytical applications. SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC₅₀ of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .

Cat. No.	Product Name	Target	Research Area